Safety and immunogenicity of the ChAdOx1-MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK.
Journal article
Borthwick N. et al, (2024), Lancet Microbe
PD-1 blockade enhances HIV-1 vaccine-induced CD8⁺ T-cell responses in PWH early ART-treated
Preprint
Marin M. et al, (2024)
Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines.
Journal article
Del Moral-Sánchez I. et al, (2024), NPJ Vaccines, 9
Therapeutic vaccination following early antiretroviral therapy elicits highly functional T cell responses against conserved HIV-1 regions.
Journal article
Kopycinski J. et al, (2023), Sci Rep, 13
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.
Journal article
Bailón L. et al, (2022), Nat Med